20 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Gainers

• CymaBay Therapeutics, Inc. CBAY shares increased by 144.02% to $4.49 during Tuesday's pre-market session. The most recent rating by Cantor Fitzgerald, on May 12, is at Overweight, with a price target of $15.

• Gamida Cell, Inc. GMDA shares moved upwards by 67.40% to $7.60. The most recent rating by HC Wainwright & Co., on Apr 27, is at Buy, with a price target of $15.

• Helius Medical, Inc. HSDT shares moved upwards by 54.12% to $0.66.

• Novavax, Inc. NVAX stock rose 48.90% to $36.48. The most recent rating by H.C. Wainwright, on May 12, is at Buy, with a price target of $50.

• Akorn, Inc. AKRX shares moved upwards by 45.31% to $0.37.

• Macrogenics, Inc. MGNX stock rose 21.12% to $31.88. The most recent rating by Credit Suisse, on May 6, is at Outperform, with a price target of $13.

• Fluidigm, Inc. FLDM shares rose 12.04% to $5.49.

• Redhill Biopharma, Inc. RDHL shares moved upwards by 10.50% to $8. The most recent rating by H.C. Wainwright, on Mar 5, is at Buy, with a price target of $14.

• Diffusion Pharmaceuticals, Inc. DFFN shares rose 10.20% to $0.81.

• Guardion Health Sciences, Inc. GHSI stock increased by 10% to $0.55.

Losers

• Genfit, Inc. GNFT shares decreased by 65.48% to $7.49 during Tuesday's pre-market session. The most recent rating by SVB Leerink, on May 12, is at Outperform, with a price target of $20.

• Nabriva Therapeutics, Inc. NBRV stock declined 14.93% to $0.62. According to the most recent rating by H.C. Wainwright, on Apr 9, the current rating is at Neutral.

• Marker Therapeutics, Inc. MRKR shares fell 10.08% to $2.23. The most recent rating by Piper Sandler, on May 12, is at Neutral, with a price target of $2.

• DBV Technologies, Inc. DBVT stock decreased by 9.42% to $5.58. The most recent rating by Citigroup, on Apr 6, is at Buy, with a price target of $10.

• Cellect Biotechnology, Inc. APOP shares declined 8.86% to $3.60.

• Akebia Therapeutics, Inc. AKBA shares declined 6.61% to $12. The most recent rating by JP Morgan, on May 6, is at Overweight, with a price target of $18.

• Ra Medical Systems, Inc. RMED stock declined 5.50% to $1.03. The most recent rating by Cantor Fitzgerald, on Mar 11, is at Neutral, with a price target of $2.

• Tilray, Inc. TLRY stock declined 4.08% to $7.75. The most recent rating by Cantor Fitzgerald, on May 11, is at Neutral, with a price target of $7.

• Cellectis, Inc. CLLS shares fell 3.09% to $14.75. The most recent rating by Goldman Sachs, on Mar 6, is at Sell, with a price target of $11.

• Ocugen, Inc. OCGN shares fell 3.03% to $0.32.